281 related articles for article (PubMed ID: 20564543)
21. Endostatin down-regulates soluble guanylate cyclase (sGC) in endothelial cells in vivo: influence of endostatin on vascular endothelial growth factor (VEGF) signaling.
Schmidt A; Wenzel D; Thorey I; Werner S; Fleischmann BK; Bloch W
Endothelium; 2005; 12(5-6):251-7. PubMed ID: 16410224
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis--a new target for future therapy.
Pandya NM; Dhalla NS; Santani DD
Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
[TBL] [Abstract][Full Text] [Related]
23. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
24. Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
Hsu SC; Ou CC; Chuang TC; Li JW; Lee YJ; Wang V; Liu JY; Chen CS; Lin SC; Kao MC
Cancer Lett; 2009 Aug; 281(1):108-16. PubMed ID: 19332363
[TBL] [Abstract][Full Text] [Related]
25. The interaction of radiation therapy and antiangiogenic therapy.
O'Reilly MS
Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
[TBL] [Abstract][Full Text] [Related]
26. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
27. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
[TBL] [Abstract][Full Text] [Related]
28. Anti-vascular endothelial growth factor therapy for neovascular ocular diseases other than age-related macular degeneration.
Ciulla TA; Rosenfeld PJ
Curr Opin Ophthalmol; 2009 May; 20(3):166-74. PubMed ID: 19381089
[TBL] [Abstract][Full Text] [Related]
29. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis.
Hicklin DJ; Ellis LM
J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754
[TBL] [Abstract][Full Text] [Related]
30. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
31. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
Cao Y
Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic strategies in breast cancer management.
Giovannini M; Aldrighetti D; Zucchinelli P; Belli C; Villa E
Crit Rev Oncol Hematol; 2010 Oct; 76(1):13-35. PubMed ID: 20702105
[TBL] [Abstract][Full Text] [Related]
33. VEGF targeted therapy in acute myeloid leukemia.
Rodriguez-Ariza A; Lopez-Pedrera C; Aranda E; Barbarroja N
Crit Rev Oncol Hematol; 2011 Nov; 80(2):241-56. PubMed ID: 21035354
[TBL] [Abstract][Full Text] [Related]
34. Targeting tumor angiogenesis.
Gaur P; Bose D; Samuel S; Ellis LM
Semin Oncol; 2009 Apr; 36(2 Suppl 1):S12-9. PubMed ID: 19393831
[TBL] [Abstract][Full Text] [Related]
35. Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice.
Lignet F; Benzekry S; Wilson S; Billy F; Saut O; Tod M; You B; Adda Berkane A; Kassour S; Wei MX; Grenier E; Ribba B
J Theor Biol; 2013 Mar; 320():86-99. PubMed ID: 23261980
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic agents in natural products for the treatment of gynecologic disorders.
Aghamohammadi A; Hosseinimehr SJ
Nutr Cancer; 2014; 66(2):206-13. PubMed ID: 24410431
[TBL] [Abstract][Full Text] [Related]
37. Serotonin activates angiogenic phosphorylation signaling in human endothelial cells.
Zamani A; Qu Z
FEBS Lett; 2012 Jul; 586(16):2360-5. PubMed ID: 22683950
[TBL] [Abstract][Full Text] [Related]
38. Antiangiogenic Effect of Flavonoids and Chalcones: An Update.
Mirossay L; Varinská L; Mojžiš J
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29271940
[TBL] [Abstract][Full Text] [Related]
39. Antiangiogenic Effect of Dopamine and Dopaminergic Agonists as an Adjuvant Therapeutic Option in the Treatment of Cancer, Endometriosis, and Osteoarthritis.
Mendoza-Torreblanca JG; Cárdenas-Rodríguez N; Carro-Rodríguez J; Contreras-García IJ; Garciadiego-Cázares D; Ortega-Cuellar D; Martínez-López V; Alfaro-Rodríguez A; Evia-Ramírez AN; Ignacio-Mejía I; Vargas-Hernández MA; Bandala C
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373348
[TBL] [Abstract][Full Text] [Related]
40. Angiogenesis as a potential target of pharmaconutrients in cancer therapy.
Granci V; Dupertuis YM; Pichard C
Curr Opin Clin Nutr Metab Care; 2010 Jul; 13(4):417-22. PubMed ID: 20453647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
